Use of opioid antagonists
AssigneeThe University of Chicago
InventorsJonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
Claims20
A method of treating a disorder characterized by hyperproliferation of cells overexpressing mu-opioid receptors, comprising administering to a subject in need thereof an effective amount of a peripheral opioid antagonist which is not a quaternary derivative of noroxymorphone.
A method of inhibiting a cancer which comprises cells that overexpress mu-opioid receptors compared to non-cancerous cells, comprising contacting the cancer cells with an effective amount of a peripheral opioid antagonist which is not a quaternary derivative of noroxymorphone.
A method of attenuating tumor growth of a cancer, metastasis of a cancer, or both, in which the cancer comprises cells that overexpress mu-opioid receptors, comprising administering to a subject in need thereof an effective amount of a peripheral mu-opioid antagonist which is not a quaternary derivative of noroxymorphone to attenuate the growth and/or metastasis.
A method of achieving an effect in a subject, comprising administering to the subject an effective amount of a peripheral mu-opioid antagonist which is not a quaternary derivative of noroxymorphone, wherein the effect is inhibiting cellular hyperproliferation, treating, cancer, inhibiting tumor growth or treating an autoimmune disease.
Dependencies are inferred from the claim text.